AQSZF Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals, Inc. focuses on the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.11    OTCQB
As of 06/14/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Canada
Country of incorporation:  
IPO date:  06/16/2015
Outstanding shares:  132,634,431
Average volume:  19,000
Market cap:   $14,974,427
Current dividend yield:  0.00%
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy